IR-783 inhibits breast cancer cell proliferation and migration by inducing mitochondrial fission

PANTONG LI¹, YU LIU¹, WUYI LIU², GUOBING LI², QIN TANG², QIAN ZHANG², FANING LENG², FANGFANG SHENG², CHANGPENG HU², WENJING LAI², YALI LIU², MIN ZHOU², JINGBIN HUANG², HUYUE ZHOU², RONG ZHANG² and YU ZHAO¹

¹Department of Pharmacy, The University-Town Hospital of Chongqing Medical University, Chongqing 401331; ²Department of Pharmacy, Xinqiao Hospital, Army Medical University, Chongqing, 400037, P.R. China

Received January 2, 2019; Accepted May 31, 2019

DOI: 10.3892/ijo.2019.4821

Abstract. IR-783, a near-infrared heptamethine cyanine dye, has been reported to possess cancer targeting and anticancer effects; However, the molecular mechanism by which IR-783 exhibits anti-breast cancer activity is unclear. In the present study, the inhibitory effects of IR-783 on the proliferation and migration of breast cancer cells were investigated. Our results revealed that IR-783 inhibited MDA-MB-231 and MCF-7 cell proliferation in a dose- and time-dependent manner by inducing cell cycle arrest at the G0/G1 phase. In addition, a Transwell assay demonstrated that IR-783 treatment suppressed the migratory ability of MDA-MB-231 and MCF-7 cells. Furthermore, IR-783 treatment decreased the expression levels of matrix metalloproteinase (MMP)-2 and MMP-9 in MDA-MB-231 cells. Furthermore, IR-783 induced MDA-MB-231 and MCF-7 cell mitochondrial fission, and also decreased the levels of ATP. This was accompanied with a decrease in polymerized filamentous actin, which is the fundamental component of filopodia at the cell surface. Collectively, the results of the present study demonstrated that IR-783 inhibited the proliferation and migration of MDA-MB-231 and MCF-7 cells by inducing mitochondrial fission and subsequently decreasing ATP levels, resulting in cell cycle arrest and filopodia formation suppression. These findings suggest that IR-783 may be developed into an effective novel drug for treating breast cancer.

Introduction

Breast cancer is a deadly form of cancer and the main cause of cancer-associated mortality among women worldwide (1). Surgical resection, radiotherapy, chemotherapy and molecular-targeted therapy are the main methods of clinical breast cancer treatment (2). At present, improvements in early diagnostic methods and treatment strategies have led to notable decreases in the mortality rate; however, a considerable portion of patients eventually succumb with tumor recurrence and drug resistance (3,4). Therefore, it is crucial to develop novel and alternative therapeutic agents for the treatment of breast cancer.

Near infrared (NIR) has a high potential in the diagnosis and treatment of various diseases, including colorectal cancer, gastric cancer and kidney cancer (5-7), owing to its well-visualized and notable tissue permeability properties (8). Of all types of NIR agents, IR-783 has received increasing attention for its excellent imaging and tumor targeting properties (9,10). Previously, several studies have revealed that IR-783 can be specifically taken up and enriched by cancer cells, targeting tumors of the brain, prostate and colon with low-toxicity for normal tissues (10-12). In recent years, researchers have reported that IR-783 possessed the ability to reduce the viability of cancer cells via pH switchable photothermal therapy and photodynamic therapy (13,14). In addition, our group previously reported that IR-783 decreased MDA-MB-231 cell viability and promoted mitochondrial apoptosis of human breast cancer cells (15,16).

Mitochondria are important double-membrane cellular organelles, which are essential for cell homeostasis and survival, as well as generating the majority of cellular energy in the form of adenosine triphosphate (ATP) (17-19). Furthermore, mitochondria are dynamic organelles that undergo continuous fission and fusion; the structure and function of which are highly regulated to meet the physiological needs of the cell (20,21). The imbalance of fission and fusion, of mitochondria leads to structural changes and dysfunction of the mitochondria, and serves an important role in cell-cycle progression, apoptosis, mitophagy and ATP production (15,21-23). Importantly, mitochondrial dynamics are essential for cell proliferation, development, death and diseases (24). Additionally, previous
studies have demonstrated that IR-783 promoted breast cancer cells apoptosis by inducing mitochondrial fission (15). Therefore, we hypothesized that mitochondria may also contribute to IR-783-induced inhibition of breast cancer cell proliferation and migration.

In the present study, we aimed to investigate the inhibitory effects of IR-783 on breast cancer cell proliferation and migration. Our results indicated that IR-783 inhibited MDA-MB-231 and MCF-7 cell proliferation by inducing cell cycle arrest at the G0/G1 phase. Additionally, IR-783 inhibited MDA-MB-231 and MCF-7 cell migration, which was accompanied with inhibiting filopodia formation with reductions in filamentous actin (F-actin) polymerization. Furthermore, mechanistic analysis revealed that IR-783 treatment induced mitochondrial fission through inhibiting the expression of mitochondrial fusion proteins optic atrophy 1 (OPA1), mitofusin 1 (Mfn1) and mitofusin 2 (Mfn2), but promoting that of the fission proteins, mitochondrial fission factor (MFF), mitochondrial fission 1 protein (Fis1) and dynamin-related protein 1 (Drp1). Our data indicated the underlying mechanism of IR-783 on inhibiting breast cancer cell proliferation and migration, and provide a mechanistic basis for the potential application of IR-783 in the treatment of breast cancer.

Materials and methods

Chemicals and antibodies. The NIR dye IR-783 was obtained from Sigma-Aldrich (Merck KGaA) and dissolved in sterile distilled water as a stock solution. The antibodies used in the present study were as follows: Anti-Cyclin D1 (cat. no. sc-8396), anti-Cyclin E (cat. no. sc-481), anti-cyclin-dependent kinase 2 (CDK2; cat. no. sc-6248), anti-OPA1 (cat. no. sc-393296), anti-Mfn1 (cat. no. sc-1666447), anti-Mfn2 (cat. no. sc-515647), anti-MFF (cat. no. sc-398617), anti-Fis1 (cat. no. sc-376447) and anti-Drp1 (cat. no. sc-271583) were obtained from Santa Cruz Biotechnology, Inc. Anti-matrix metalloproteinase-2 (MMP-2; cat. no. 40994) and anti-MMP-9 (cat. no. 13667) were obtained from Cell Signaling Technology, Inc. Anti-GAPDH (cat. no. AG019-1) was obtained from Beyotime Institute of Biotechnology.

Cell culture. The human breast cancer cell lines MDA-MB-231 and MCF-7 were purchased from the American Type Culture Collection. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), all from Gibco (Thermo Fisher Scientific, Inc.). Cells were cultured at 37°C with 5% CO2 and digested every 2 days by 0.25% trypsin (Gibco; Thermo Fisher Scientific, Inc.).

MTT assay. Cells (2x10^4 cells/well) were seeded onto 96-well plates and allowed to attach. After treatment with various concentrations of IR-783 (0, 20, 40, 60, 80, 100, 120, 140 and 160 µM) for 24 h or with 80 µM IR-783 for different time intervals (0, 3, 6, 12, 24, 36, 48 and 72 h) in a 5% CO2 incubator at 37°C, cells were incubated with 20 µl MTT solution (5 mg/ml; Sigma-Aldrich; Merck KGaA), cells were treated at 37°C for 4 h. Then, the medium was removed slowly and 150 µl dimethyl sulfoxide (Eastman Kodak) was added to dissolve the formazan crystals. The proliferation of cells was determined using a microplate reader (Varioskan Flash; Thermo Fisher Scientific, Inc.) at 490 nm. All results were repeated in three independent experiments.

Clone formation assay. Cells were digested by 0.25% trypsin and seeded in a 5-cm sterile petri-dish at a density of 100 cells per dish overnight. Then, cells were treated with different concentrations of IR-783 (0, 80 and 160 µM) the next day and incubated at 37°C. After 24 h, the supernatant was discarded carefully and fresh DMEM with 10% FBS was added. Cells were cultured for 2-3 weeks until clones were visible. After removing culture medium, clones were washed for three times with PBS, fixed with 4% paraformaldehyde for 15 min, then stained with 0.1% crystal violet for 10 min at room temperature. Clones were counted using Photoshop CS6 software (version 13.0; Adobe Systems, Inc.). All results were performed for three independent times.

5'-Ethynyl-2'-deoxyuridine (EdU) assay. Cell proliferation was assessed with a BeyoClick™ EDU-488 imaging Kit (cat. no. C0071S; Beyotime Institute of Biotechnology). Cells were inoculated onto slides of 24-well plates at a density of 1x10^4 cells/well and incubated overnight at 37°C. Then, IR-783 (0, 80 and 160 µM) was added to cells and cultured for 24 h. Subsequently, cells were exposed to 20 µM EdU for 2 h at 37°C. Cells were then fixed with 4% paraformaldehyde for 15 min, followed by the addition of 200 µl 0.5% Triton X-100 (AppliChem GmbH) for 10 min to increase cell permeability at room temperature. After washing with PBS for three times, 200 µl of click reaction solution was added according to the instructions and cells were incubated for another 30 min at room temperature in the dark. Next, cells were washed again and stained with 100 µl of Hoechst 33342 for 30 min at room temperature. The samples were analyzed and imaged with a fluorescence microscope (BX63; Olympus Corporation) at x20 magnification. EdU-positive cells were analyzed in three randomly selected field by using Photoshop CS6 software (version 13.0; Adobe Systems, Inc.).

Cell cycle analysis. Cell cycle analysis was performed by flow cytometry. Cells were seeded in a 6-well plate at a density of 1x10^6 cells/well and cultured overnight. IR-783 (0, 80 and 160 µM) was added and incubated for 24 h. Cells were collected and washed twice with cold PBS, then fixed in cold 75% ethanol at 4°C overnight. Subsequently, the cells were washed with cold PBS and incubated with 50 µg/ml RNase and 100 µg/ml propidium iodide (cat. no. 556547; BD Biosciences) for 30 min at 37°C in the dark. The samples were analyzed with a flow cytometer (FACScan) using CellQuest software (version 5.1) (both from BD Biosciences).

Wound healing assay. The migration ability of MDA-MB-231 cells was assessed using a wound healing assay. Cells (5x10^3 cells/well) were cultured in 6-well plates and allowed to grow to 80-90% confluence. Scratches of predetermined length were created with a 200 µl pipette tip. After washing the scratched cells with PBS, IR-783 (0, 80 and 160 µM) were added and incubated for 24 or 48 h at 37°C. The images of wounds were imaged using a Cell Imaging System (Carl Zeiss AG). The wound width was measured using ImageJ software.
4% paraformaldehyde for 15 min and permeabilized with 80 µM IR-783 for 24 h at 37˚C, then cells were fixed with staining of the actin cytoskeleton, cells were treated with using a laser-scanning confocal microscope (LSM780NLO; Carl Zeiss AG) at x63 magnification, the representative images were randomly selected from five fields of view.

**Western blotting.** MDA-MB-231 cells (1x10⁴ cells/ml) were treated with IR-783 for 24 h, then harvested and lysed in cell lysis solution (cat. no. P0013; Beyotime Institute of Biotechnology) with PMSF. A BCA protein assay kit (cat. no. P0010, Beyotime Institute of Biotechnology) was used to quantify protein concentration. Proteins were quantified via a BCA assay. The proteins lystate samples (15, 30 or 60 µg) were separated via 10-12% SDS-PAGE and then transferred to polyvinylidene difluoride membranes (EMD Millipore). The membranes were blocked with 5% skim milk for 2 h at room temperature and incubated with specific primary antibodies overnight at 4°C. The following antibodies were used: Anti-Cyclin D1 (diluted 1:500), anti-Cyclin E (diluted 1:500), anti-CDK2 (diluted 1:500), anti-OPA1 (diluted 1:500), anti-Mfn1 (diluted 1:500), anti-Mfn2 (diluted 1:500), anti-MFF (diluted 1:500), anti-Fis1 (diluted 1:500), anti-Drp1 (diluted 1:500), anti-MMP-2 (diluted 1:1000), anti-MMP-9 (diluted 1:1000) and anti-GAPDH (diluted 1:2,000). Membranes were washed three times with TBST and then incubated with anti-rabbit (diluted 1:50,000, cat. no. 100204) or anti-mouse (diluted 1:50,000, cat. no. 130639) horseradish peroxidase secondary antibodies (Kirkegaard & Perry Laboratories Inc.) for 2 h at room temperature. The immunoreactive bands were visualized using an enhanced chemiluminescence kit (Amersham ECL or ECL Plus; GE Healthcare Life Sciences); protein expression was quantified using Quantity One software (version 4.6; Bio-Rad Laboratories, Inc.).

**Statistical analysis.** All data were presented as the mean ± standard deviation using GraphPad prism 6.0 software (GraphPad Software, Inc.). Statistical analysis between different groups were determined using one-way analysis of variance with a Dunnett’s or Tukey’s post-hoc test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**IR-783 suppresses MDA-MB-231 and MCF-7 cell proliferation.** The chemical structure of IR-783 is presented in Fig. 1A. First, we evaluated the inhibitory effects of IR-783 on MDA-MB-231 and MCF-7 cells using an MTT assay. As shown in Fig. 1B and C, we reported that IR-783 treatment significantly decreased cell proliferation in a dose- and time-dependent manner compared with the control. To further confirm the effects of IR-783 on cell proliferation, a colony formation assay was performed. As presented in Fig. 1D, our results indicated that the number of colonies formed in IR-783-treated group was significantly reduced in MDA-MB-231 and MCF-7 breast cancer cells compared with the control. Furthermore, the effects of IR-783 on cell proliferation in MDA-MB-231 and MCF-7 cells was examined with an EdU assay. The results revealed significant fewer EdU-positive cells following treatment with IR-783.
compared with the control (Fig. 1E). Taken together, these findings demonstrated that IR-783 suppresses MDA-MB-231 and MCF-7 cell proliferation.

**IR-783 induces MDA-MB-231 and MCF-7 cell cycle arrest at the G0/G1 phase.** To further determine the underlying mechanisms of IR-783-induced inhibition of the growth of MDA-MB-231 and MCF-7 cells, we examined the effects of IR-783 on MDA-MB-231 and MCF-7 cell cycle distribution. After treatment with IR-783 (0, 80 and 160 µM) for 24 h, the proportion of MCF-7 cells in G0/G1 phase significantly increased from 34.57% (without IR-783 treatment) to 57.45% (cells treated with 160 µM IR-783); the proportion of MDA-MB-231 cells in G0/G1 phase significantly increased from 37.04% (without IR-783 treatment) to 58.26% (cells treated with 160 µM IR-783) (Fig. 2A). No significant differences in the number of cells in S and G2/M phase were observed following treatment with IR-783. These results suggested that IR-783 induced MDA-MB-231 and MCF-7 cell cycle arrest at the G0/G1 phase. Furthermore, we detected alterations in the expression of G0/G1 phase-related proteins Cyclin D1, Cyclin E and CDK2 of MDA-MB-231 cells using western
blotting. The results demonstrated that IR-783 significantly reduced the expression of Cyclin D1, Cyclin E and CDK2 compared with the control (Fig. 2B). These results suggested that IR-783 induces cell cycle arrest at G0/G1 phase.

**IR-783 inhibits MDA-MB-231 and MCF-7 cell migration.** In addition, a Transwell assay was conducted to examine the effects of IR-783 on MDA-MB-231 and MCF-7 cell migration; a wound healing assay was performed to determine the effects of IR-783 on MDA-MB-231 cell migration. The Transwell assay revealed that IR-783 significantly inhibited the migration of MDA-MB-231 and MCF-7 cells compared with the control (Fig. 3A). Furthermore, the wound healing assay indicated that IR-783 significantly decreased the migration of MDA-MB-231 cells in a dose- and time-dependent manner (Fig. 3B). MMPs, especially MMP-2 and MMP-9, have been reported to be critical regulators involved in tumor migration (25). Thus, western blotting was conducted to investigate whether IR-783 affected the expression of MMP-2 and MMP-9 in MDA-MB-231 cells. The western blot assay demonstrated that IR-783 treatment significantly decreased the expression of MMP-2 and MMP-9 in a concentration-dependent manner compared with the control group (Fig. 3C). Collectively, these results indicated that IR-783 inhibits MDA-MB-231 and MCF-7 cell migration.

**IR-783 inhibits filopodia formation by reducing F-actin formation.** Filopodia are critical actin cytoskeletal protrusion structures, and are key factors involved in tumor metastasis (26). Metastatic tumor cells contain numerous filopodia, and the numbers of filopodia are correlated with the invasiveness and migration (27). F-actin is the fundamental component of the cytoskeleton that supports the structure of filopodia, stabilizing them in migrating cancer cells, and it is involved in filopodium formation via the polymerization of actin into bundles under the cell membrane (28). The present study

---

**Figure 2.** IR-783 induces MDA-MB-231 and MCF-7 cell cycle arrest at G0/G1 phase. (A) MDA-MB-231 and MCF-7 cells were collected after treatment with IR-783 (0, 80 and 160 µM) for 24 h and analyzed by flow cytometry. The distribution (%) of G0/G1 and S phases was measured by ModFit LT 5.0 software. (B) The expression levels of G0/G1 phase regulators Cyclin D1, Cyclin E and CDK2 of MDA-MB-231 cell were detected by western blotting. Quantity One software was used to quantify the relative expression of the detected proteins; GAPDH was used as loading control. All data are expressed as the mean ± standard deviation. (n=3). **P<0.01, ***P<0.001 vs. the control group. CDK2, cyclin-dependent kinase 2.
reported that the control cell group exhibited a large number of F-actin filaments in the marginal zone and cytoplasm. Incubation with IR-783 induced MDA-MB-231 and MCF-7 cell shrinkage and a marked decrease in the abundance of F-actin (Fig. 4). Collectively, these data suggested that IR-783 inhibits filopodia formation by reducing F-actin formation.

IR-783 induces ATP depletion and mitochondrial fission in MDA-MB-231 and MCF-7 cells. ATP, which provides energy for cells, serves an important role in cell life and is central to the fate of cancer cells (29). It has been reported that cancer cells have higher ATP levels than normal cells, and decreases in ATP levels of cancer cells indicates alterations in cancer
As presented in Fig. 5A, the MDA-MB-231 and MCF-7 cellular ATP levels decreased in a dose-dependent manner in response to the IR-783. Mitochondria are the main organelle in cells involved in the synthesis of ATP. ATP depletion has been reported as an indicator of mitochondrial dysfunction (30). Our transmission electron microscopy results showed that mitochondria of MDA-MB-231 cells swelled; the cristae of mitochondria disintegrated partly as demonstrated by the transparent electronic density area in IR-783 treated cells. On the contrary, the mitochondria presented a slender flat structure in control cells, suggesting that IR-783 induced mitochondrial injury in MDA-MB-231 cells (Fig. 5B). The morphology of mitochondria is dynamically controlled by fission and fusion (20). When alterations in mitochondrial morphology occurred, the balance between fission and fusion is disrupted (20). Next, MDA-MB-231 and MCF-7 cells were stained with MitoTracker Red CMXRos to assess the influence of IR-783 on mitochondrial dynamics. Confocal laser scanning microscopy results revealed that IR-783 treatment promoted mitochondrial fission, as observed by a marked increase in number of small, punctate mitochondria in IR-783 treated cells compared with control cells, which exhibited stable and elongated structures (Fig. 5C). To further confirm these results, western blotting was used to evaluate the expression of mitochondrial fusion regulators OPA1, Mfn1 and Mfn2, and the expression of mitochondrial fission regulators MFF, Fis1 and Drp1 which affect mitochondrial dynamics at the outer mitochondrial membrane. We found that exposure of MDA-MB-231 cells to IR-783 resulted in a significant decrease in the expression of OPA1, Mfn1 and Mfn2, and increased the levels of MFF, Fis1 and Drp1 compared with the control (Fig. 5D and E). These results suggested that IR-783 induces mitochondrial fission and subsequent ATP depletion in MDA-MB-231 and MCF-7 cells.

### Discussion

In recent years, NIR imaging has received increasing attention in the diagnosis and treatment of cancer. IR-783 is a promising imaging NIR dye, and it possesses anti-cancer activity, specific towards prostate, bladder and breast cancers (31,32). IR-783 was determined to induce breast cancer cell apoptosis in vitro and in vivo (15); however, the effects of IR-783 on breast cancer cell proliferation and migration requires further investigation. In the present study, we found that IR-783 significantly suppressed the proliferation and colony formation ability of MDA-MB-231 and MCF-7 cells through inhibition of cell cycle progression and filopodia formation.

Cancer cells have greater proliferation ability compared with normal cells. Proliferation of cancer cells is the essential steps of tumor incidence and development (33). In the present study, IR-783 treatment effectively inhibited the proliferation and colony formation ability of MDA-MB-231 and MCF-7 cells. Additionally, IR-783 was reported to induce cell cycle arrest at the G0/G1 phase in a dose-dependent manner in the present study. The cell cycle is a physiological process comprising G0/G1, S
and G2/M phases. Cyclins bind to corresponding CDKs and activate them to regulate the transition of cell cycle phases, which serves a key role in regulation of the cell cycle (34). In the present study, Cyclin D1, Cyclin E and CDK2 were significantly downregulated in MDA-MB-231 cells following IR-783 treatment. These findings suggested that IR-783 induced cell
cycle arrest at the G0/G1 phase by downregulating Cyclin D1, Cyclin E and CDK2. Direct analysis of DNA synthesis is one of the most accurate ways of assessing cell proliferation. Thus, we performed an EdU assay, an immunochemical method for the detection of the nucleotide analog which is incorporated into replicated DNA (35). We observed that the number of EdU-positive cells was significantly lower in IR-783-treated cells compared with control group cells; These findings indicated that IR-783 inhibited MDA-MB-231 and MCF-7 cell proliferation.

Metastasis remains the cause of 90% of mortalities from solid tumors (36). The migration and invasive abilities of tumor cells are essential for tumor metastasis. Members of the MMP family are commonly considered as biomarkers for cancers. In particular, MMP-2 and MMP-9 are typical members among the MMPs, and are able to degrade type IV collagen, which induces cancer cell metastasis by promoting the primary tumor migration (37,38). In the present study, IR-783 treatment markedly inhibited wound-closure ability of MDA-MB-231 in a wound healing assay and the migration ability of MDA-MB-231 and MCF-7 cells was also suppressed as determined via a Transwell assay. In addition, the expression of MMP-2 and MMP-9 in MDA-MB-231 cells were decreased after IR-783 treatment. On the contrary, previous researchers have revealed that filopodia are associated with cancer cell migration and invasion (39). Furthermore, cancer cell migration can be suppressed by inhibiting filopodia formation ability in vitro (40). F-actin has been reported as a key factor in filopodia, and participated in filopodia extension and retraction at the cell surface. In the present study, IR-783 inhibited MDA-MB-231 and MCF-7 cell filopodia formation, while decreases in polymerized F-actin were detected, indicating that the metastatic ability of MDA-MB-231 and MCF-7 cell was attenuated by IR-783 through inhibiting filopodia formation.

It has been reported that blocking ATP production can inhibit filopodia formation and cell migration (41). We observed that IR-783 treatment inhibited MDA-MB-231 and MCF-7 cell migration and filopodia formation. In addition, we assessed the content of ATP using a microplate reader. The results revealed that IR-783 treatment decreased the levels of ATP in MDA-MB-231 and MCF-7 cells in a dose-dependent manner. ATP depletion has also been reported as an indicator of mitochondrial dysfunction (30). Our results of transmission electron microscopy and immunofluorescence analysis showed that IR-783 treatment led to mitochondrial injury and a notable increase in mitochondrial fission, evidenced by more small, punctate, swelled, cristae disintegrating and vacant mitochondria. Abnormal mitochondrial morphology is attributed to imbalances in mitochondrial fission and fusion (21,42). Numerous proteins and pathways are involved in mitochondrial fusion and fission, while the initial fusion of mitochondria requires the presence of OPA1, Mfn1 and Mfn2 at the inner or outer mitochondrial membrane (21,43). Whereas fission is primarily regulated by the proteins: Drp1, Fis1 and MFF (43). After cells are stimulated under fission-promoting conditions, outer mitochondrial membrane proteins Fis1 and MFF can recruit Drp1 translocation from the cytosol to the mitochondria, and initiate mitochondrial fission (44). Our findings of western blotting demonstrated that IR-783 treatment significantly decreased the expression of the mitochondrial fusion proteins OPA1, Mfn1 and Mfn2, whereas that of the mitochondrial fission proteins Drp1, Fis1 and MFF had increased in MDA-MB-231 cells. Collectively, these results demonstrated that IR-783 inhibited ATP production by inducing mitochondrial fission.

In summary, these data demonstrated that IR-783 inhibited MDA-MB-231 and MCF-7 cell proliferation and migration by inducing mitochondrial fission and subsequently decreasing ATP levels, resulted in cell cycle arrest and filopodia formation inhibition. Our findings could provide a novel mechanistic basis for the application of IR-783 in the treatment of breast cancer.

Acknowledgements

Not applicable.

Funding

This work was supported by the National Natural Science Foundation of China (grant nos. 81874357, 81703481 and 81801273), Natural Science Foundation of Chongqing (grant nos. cstc2018jcyjA00183 and cstc2015jcyjA10011).

Availability of data and materials

The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.

Authors' contributions

PL, YZ and RZ conceived and designed the study. PL, FS, YL, WL, MZ and QT performed the experiments. FL, JH, HZ, CH and WL analyzed the data. PL, YL and YZ wrote the manuscript. GL and QZ reviewed and revised the manuscript. HZ, CH and WL analyzed the data. PL, YL, WL, MZ and QT performed the experiments. FL, JH, HZ, CH and WL analyzed the data. PL, YL and YZ wrote the manuscript. GL and QZ reviewed and revised the manuscript. All authors read and approved the manuscript and agreed to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the report work are appropriately investigated and resolved.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J and Shi B: Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res 5: 2929-2943, 2015.
2. Wang B, Xing Z, Wang F, Yuan X and Zhang Y: Fangchinoline inhibits migration and causes apoptosis of human breast cancer MDA-MB-231 cells. Oncol Lett 14: 5307-5312, 2017.
Archer SL: Mitochondrial dynamics - mitochondrial fission and fusion in human stem cells. Nat Rev Mol Cell Biol 11: 872-884, 2010.

Ezumi T and Blasig I: Mitochondria fusion and fission in cell life and death. Nat Rev Mol Cell Biol 11: 872-884, 2010.